Malignant ascites mostly appears in the late stage of tumor disease, and patients may have received multiple courses of chemotherapy in the past, and the general condition of patients when ascites appears is not good, so systemic chemotherapy is of little value at this time, and the choice of chemotherapy regimen, drug dose and administration method should be carefully. It has been reported that weekly doses of paclitaxel administered intravenously for malignant ascites caused by gastric cancer are safe and efficacious. However, some patients with malignant ascites as the first symptom and sensitive to chemotherapy, such as ovarian cancer, can undergo tumor cytoreductive surgery combined with systemic chemotherapy based on paclitaxel, which is still effective. Phase III clinical trials have shown that paclitaxel combined with carboplatin and bevacizumab can significantly prolong progression-free survival in advanced or recurrent ovarian cancer, but the benefit on long-term survival needs to be further observed.